Literature DB >> 1517277

Effect of chemotherapy combined with caffeine for osteosarcoma.

H Tsuchiya1, H Yasutake, A Yokogawa, H Baba, Y Ueda, K Tomita.   

Abstract

Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery. All primary tumors showed complete histological response to preoperative chemotherapy consisting of three intraarterial infusions of cisplatin and caffeine without/with doxorubicin and two systemic high-dose methotrexate combined with vincristine. Limb-salvage surgery was performed in eight patients with marginal procedure, which led to the preservation of good limb function. Below-knee amputation was done in one patient with calcaneal osteosarcoma. There has been neither local recurrence nor lung metastasis in seven patients with conventional osteosarcoma during a median follow-up period of 28 months. Lung metastases leading to death were observed in one patient with small-cell osteosarcoma despite complete destruction of the primary tumor by preoperative chemotherapy. Chemotherapy combined with caffeine administration deserves further extensive and large-scale study in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517277     DOI: 10.1007/bf01211797

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  12 in total

1.  Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).

Authors:  K Winkler; S Bielack; G Delling; M Salzer-Kuntschik; R Kotz; C Greenshaw; H Jürgens; J Ritter; C Kusnierz-Glaz; R Erttmann
Journal:  Cancer       Date:  1990-10-15       Impact factor: 6.860

2.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

Authors:  K Winkler; G Beron; G Delling; U Heise; H Kabisch; C Purfürst; J Berger; J Ritter; H Jürgens; V Gerein
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

3.  Intermediate results and functional evaluation of limb-salvage surgery for osteosarcoma: an intergroup study in Japan.

Authors:  K Tomita; H Tsuchiya
Journal:  J Surg Oncol       Date:  1989-06       Impact factor: 3.454

4.  Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma.

Authors:  K C Stine; M J Hockenberry; J Harrelson; D Miner; J M Falletta
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

5.  Pediatric osteosarcoma. Successful retreatment of relapsed primary tumor and soft tissue recurrence with intraarterial cis-diamminedichloroplatin-II.

Authors:  S Epelman; J Estrada; N Jaffe; A Bianchi
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

6.  Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies.

Authors:  N Jaffe; J Knapp; V P Chuang; S Wallace; A Ayala; J Murray; A Cangir; A Wang; R S Benjamin
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

7.  Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma.

Authors:  K Tomita; H Tsuchiya
Journal:  Clin Ther       Date:  1989       Impact factor: 3.393

8.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.

Authors:  G Bacci; P Picci; P Ruggieri; M Mercuri; M Avella; R Capanna; A Brach Del Prever; A Mancini; F Gherlinzoni; G Padovani
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

9.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

10.  Caffeine enhancement of the effect of anticancer agents on human sarcoma cells.

Authors:  K Tomita; H Tsuchiya
Journal:  Jpn J Cancer Res       Date:  1989-01
View more
  5 in total

Review 1.  Cryoimmunology for malignant bone and soft-tissue tumors.

Authors:  Hideji Nishida; Norio Yamamoto; Yoshikazu Tanzawa; Hiroyuki Tsuchiya
Journal:  Int J Clin Oncol       Date:  2011-03-12       Impact factor: 3.402

2.  Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.

Authors:  Masanori Kawano; Hideji Nishida; Yasunari Nakamoto; Hiroshi Tsumura; Hiroyuki Tsuchiya
Journal:  Clin Orthop Relat Res       Date:  2010-03-16       Impact factor: 4.176

3.  Caffeine-potentiated chemotherapy for clear cell sarcoma: a report of five cases.

Authors:  Michiaki Karita; Hiroyuki Tsuchiya; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Hideji Nishida
Journal:  Int J Clin Oncol       Date:  2011-11-01       Impact factor: 3.402

4.  Outcome prediction of pulmonary metastasectomy can be evaluated using metastatic lesion in osteosarcoma patients.

Authors:  Isao Matsumoto; Makoto Oda; Tsuyoshi Yachi; Hiroyuki Tsuchiya; Yoh Zen; Go Watanabe
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

5.  Cervical subtotal en-bloc spondylectomy of C6 mesenchymal chondrosarcoma.

Authors:  Chang-Hwa Lee; Woo-Kie Min
Journal:  Eur Spine J       Date:  2015-11-10       Impact factor: 3.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.